Company intelligence / Profile preview

Vitalunga

Jerusalem, Jerusalem District, Israelvitalunga.it ↗

Ownership: Private
Development stage: Preclinical

Overview

Vitalunga has developed a novel family of orally administered small molecules that activate autophagy and mitophagy, rejuvenate cells, and have shown promising results in model organisms. The company aims to treat or prevent multiple aging-related diseases. As of the latest reports, they are preparing for preclinical studies with plans to advance toward clinical trials if funding allows. No human clinical data yet available.

Therapeutic areas: Metabolic DisordersCardiovascularNeurologyOther
Modalities: Small molecules
Industry: Biotech

Partnerships

Yissum – Technology transfer company of The Hebrew University; supports commercialization efforts.

Beyond the preview

Go deeper on Vitalunga.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitalunga.

Explore the full profile